Julita Niewęgłowska

Julita Niewęgłowska

Auto-generated profile, based on publicly available information

Julita Niewęgłowska

Uniwersytet Medyczny w Lublinie

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2022 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
KNKacper Niewęgłowski
Kacper Niewęgłowski
NWNatalia Anna Wilczek
Natalia Anna Wilczek
MRMichał Rycharski
Michał Rycharski
JNJulita Niewęgłowska
Julita Niewęgłowska
Introduction and purpose Obsessive-compulsive disorder (OCD) has an unclear etiology. Genetic and environmental factors dominate among the etiologic factors. The disorder is characterized by the presence of obsessions (repetitive and persistent thoughts, images, impulses or urges) and compulsions (rituals; repetitive behaviours or mental acts that the individual feels driven to perform in response to an obsession). This disorder has less than 4% of the population. Treatment is a long and difficult process, and the best results are with SSRIs (e.g., fluoxetine) and cognitive behavioral therapy (CBT). The aim of the study was to review articles linking gut microbiota and obsessive-compulsive disorder issues. A brief description of the state of knowledge The gut microbiota-gut-brain axis perhaps has an impact on the etiology of psychiatric diseases. Its existence has been well researched in animals. Researches suggest that there possibly may be changes in the composition of the gut microbiota in people with obsessive-compulsive disorder. Quantitative and qualitative changes in the gut microbiota composition may worsen the patient's condition. The use of probiotics may help improve the patient's condition and reduce symptoms of the disorder. Summary (conclusions) More research is needed to explore the potential impact of the gut microbiota on obsessive-compulsive disorder. This could perhaps lead to future applications of probiotics, e.g., in the adjunctive treatment of obsessive-compulsive disorder.

25 May 2022 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
KNKacper Niewęgłowski
Kacper Niewęgłowski
NWNatalia Anna Wilczek
Natalia Anna Wilczek
MRMichał Rycharski
Michał Rycharski
JNJulita Niewęgłowska
Julita Niewęgłowska
Introduction and purpose Vonoprazan is a potassium-competent acid blocker (P-CAB). It has the potential to be an alternative to proton pump inhibitors (PPIs) as it inhibits hydrochloric acid secretion. The mechanism of action is different than PPIs - vonoprazan reversibly inhibits gastric H+, K+-ATPase, while PPIs irreversibly. Vonoprazan is approved for use in Japan and the US. The aim of the study was to review articles on the use of vonoprazan instead of PPIs in the treatment of acid-related gastrological diseases and to present the results obtained. A brief description of the state of knowledge Vonoprazan is used in the treatment of acid-related gastrological diseases. The 20 mg dose is suitable for most diseases, such as treatment of ulcers during low-dose aspirin treatment, post-endoscopic submucosal dissection (post-ESD) ulcers, erosive esophagitis (EE) in gastroesophageal reflux disease (GERD), and Helicobacter pylori eradication. Summary Researches suggest that the drug is an alternative for PPIs and can be used instead of them. The main advantage of this drug over PPIs is that it works faster, more potent and long-lasting. Studies suggest that vonoprazan can be use to treatment of the acid-related diseases and may be a better choice than PPIs. Vonoprazan may have a particular use in the treatment of PPI-refractory GERD. In post-ESD ulcers, a significant benefit in treatment effects of vonoprazan over PPIs cannot be clearly concluded.